Payment Solution Disruptor xpate Expands Developer Team Amid Surge in Cross-border Ecommerce
10.5.2022 13:13:00 EEST | Business Wire | Press release
xpate, the rapidly-growing simplified cross-border payment solution provider, has announced a significant expansion of its disruptive developer team, with 35 new team members onboard to speed up building services aimed to enhance flexibility and data processing for merchants and acquirers.
The new appointments, with extensive experience at leading ecommerce platforms AliExpress, and enterprise cloud infrastructure builder Mirantis, will bring unrivalled levels of technical agility and creative user-focused design strengths to xpate.
The company’s ambitious growth plans, focused on helping customers to optimise payment flows and lower operational risk, have come to fruition over the last 12 months for the scaling company. The latest wave of developer hires takes xpate’s headcount to 135, from just three employees at the firm’s inception in 2018.
xpate’s momentum has been fuelled by the launch of breakthrough services such as its acquiring platform Links, and its Core Banking Solution (CBS) which speeds up and streamlines integration with various acquiring systems to give clients access to real-time data processing.
Supporting these services is xpate’s development of its own data warehouse, allowing the company to collect and store data in a centralised location to generate more deep analytics and reporting power for clients. Among the elevated service capabilities is the ability to offer businesses automatic reconciliation of third-party transactions, an internal monitoring and incident reporting system, and a customisable payment page for xpate’s merchants.
Mihails “Mike” Safro, CEO of xpate, comments: “The past three years have been something of a whirlwind, in terms of both the success of our product offerings and the growth of our team – specifically developers.
“Since xpate’s inception, we have worked tirelessly to build a company that combines technical ingenuity with a simplified user experience, to empower merchants to capitalise on all the opportunities in cross-border ecommerce. Our people are at the heart of our culture, and as such, we have assembled a diverse team of talented individuals who not only understand the importance of this ethos, but also offer unparalleled expertise and experience across the financial sector.
“While xpate has witnessed an incredible start to the business, we will certainly not be resting on our laurels. We are constantly working on improving our products and services, and look forward to sharing these exciting and ambitious developments with our customers throughout 2022 and beyond.”
These latest additions to the company’s team follow xpate achieving Mastercard principal member status in 2021 – a significant strategic partnership that has allowed xpate to enhance its platform, offer innovative solutions to new clients, bolster its merchant acquiring portfolio, and take advantage of an extended range of products and services to strengthen market offering.
For more information on xpate, go to: www.xpate.com.
###
About xpate
xpate is the payments platform that prioritises simplicity, speed and user experience.
We provide businesses with a single multi-fit solution that unites all of the desired payment methods to cover an extensive range of demands that otherwise require onboarding and integration with multiple partners.
#ENDS#
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005806/en/
Contact information
Press enquiries:
Jenna Walker
SkyParlour
jenna@skyparlour.com
07591 382 856
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 16:00:00 EEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom